Enzymes as indispensable markers in disease diagnosis
Enzymes have been used for disease diagnosis for many decades; however, advancements in technology like ELISA and flow cytometry-based detection have significantly increased their use and have increased the sensitivity of detection. Technological advancements in recombinant enzyme production have increased enzymatic stability, and the use of colorimetric-based and florescence-based assays has led to their increased use as biomarkers for disease detection. Enzymes like acid phosphatase, cathepsin, lactate dehydrogenase, thymidine kinase and creatine kinase are indispensable markers for diagnosing cancer, cardiovascular diseases and others. This minireview summarizes various enzymes used in disease diagnosis, their metabolic role, market value and potential as disease markers across various metabolic and other disorders.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Bioanalysis - (2024) vom: 26. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pathan, Shehabaz Usman [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Revised 26.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.4155/bio-2023-0207 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370197801 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370197801 | ||
003 | DE-627 | ||
005 | 20240327000906.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240327s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4155/bio-2023-0207 |2 doi | |
028 | 5 | 2 | |a pubmed24n1349.xml |
035 | |a (DE-627)NLM370197801 | ||
035 | |a (NLM)38530222 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pathan, Shehabaz Usman |e verfasserin |4 aut | |
245 | 1 | 0 | |a Enzymes as indispensable markers in disease diagnosis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 26.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Enzymes have been used for disease diagnosis for many decades; however, advancements in technology like ELISA and flow cytometry-based detection have significantly increased their use and have increased the sensitivity of detection. Technological advancements in recombinant enzyme production have increased enzymatic stability, and the use of colorimetric-based and florescence-based assays has led to their increased use as biomarkers for disease detection. Enzymes like acid phosphatase, cathepsin, lactate dehydrogenase, thymidine kinase and creatine kinase are indispensable markers for diagnosing cancer, cardiovascular diseases and others. This minireview summarizes various enzymes used in disease diagnosis, their metabolic role, market value and potential as disease markers across various metabolic and other disorders | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a acid phosphatase | |
650 | 4 | |a alkaline phosphatase | |
650 | 4 | |a aminotransferase | |
650 | 4 | |a biomarkers | |
650 | 4 | |a cancer | |
650 | 4 | |a cathepsin | |
650 | 4 | |a creatine kinase | |
650 | 4 | |a diagnostic enzymes | |
650 | 4 | |a esterase | |
650 | 4 | |a glycogen phosphorylase | |
650 | 4 | |a lactate dehydrogenase | |
650 | 4 | |a liver diseases | |
650 | 4 | |a lysozyme | |
650 | 4 | |a thymidine kinase | |
700 | 1 | |a Kharwar, Akash |e verfasserin |4 aut | |
700 | 1 | |a Ibrahim, Madaje Amir |e verfasserin |4 aut | |
700 | 1 | |a Singh, Shashi Bala |e verfasserin |4 aut | |
700 | 1 | |a Bajaj, Priyanka |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g (2024) vom: 26. März |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:26 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0207 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 26 |c 03 |